The identification of LCNEC tumors with high ERBB2 expression levels suggests that a subset of these tumors might be sensitive to ERBB2 inhibitors, similar to ERBB2-positive gastric cancer and breast cancer (Asaoka et al. 2011; Stern 2012; Kumler et al. 2014). This evidence concerns the gene ERBB2 and large cell neuroendocrine carcinoma.